Kymera Therapeutics, Inc. <KYMR.O>: Morgan Stanley Raises Target Price to $135 From $119
KYMR•Related News
Shift4 slides after cutting annual revenue forecast
FOUR•
Iovance publishes corporate presentation highlighting Amtagvi TIL therapy rollout and pipeline expansion in solid tumors
IOVA•
Ralph Lauren Q1 FY27 EPS rises 22% to $4.28; revenue increases 14% to $2 billion
RL•
Insight Enterprises Q2 FY26 net earnings climb 65% to $77.6 million; net sales rise 15% to $2.4 billion
NSIT•
MBX Biosciences Q2 FY26 net loss widens to $37.1 million; R&D expenses rise to $31 million
MBX•